您好,歡迎訪問中山大學腫瘤防治中心官方網站!
內部網 職工郵箱 圖書館 OA系統 醫生門戶 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 曾維安

    職務:手術麻醉科主任
    職稱:教授,主任醫師,博士生導師
    專長:單肺通氣,疼痛發病機制研究,神經病理性疼痛與癌痛的治療
    基本情況
    職務:手術麻醉科行政負責人、主任導師
    職稱:教授,主任醫師,博士生導師
    教育及工作經歷:
    1999年4月-至今 中山大學腫瘤防治中心,手術麻醉科
    1993年11月-1998年10月 日本岐阜大學,博士研究生
    1998年11月-1999年3月 日本岐阜大學醫學部,研究學者
    1989年12月-1992年5月  日本名古屋大學醫學部,研究生
    主攻方向: 
    1.單肺通氣
    2.疼痛發病機制研究,神經病理性疼痛與癌痛的治療
      曾維安,中山大學腫瘤防治中心手術麻醉科行政負責人,主任導師、教授、主任醫師、博士生導師。
      從事臨床麻醉研究與實踐三十余年。先后主持五項國家自然基金面上項目和十余項省部級課題。發表高水平論文四十余篇,分別在Anesthesiology, JBC, BJA, J Pain, Ann Surg Oncol, Anesth Analg, iscience, Brain Behavior and Immunity等。

    一、指導研究生畢業
      截至2020年指導博士研究生13名,碩士研究生15名。在站博士后8名。

    二、主持科研項目
    1)2019-至今,國家自然科學基金課題,circ-Nrxn1/HIF-1α/NOX2軸調控脊髓小膠質細胞M1/M2極化介導化療外周神經損傷的機制研究。
    2)2019.01-2021.12,臨床科學家,中心高層次人才特殊支持項目。   
    3)2018-至今,國家重點研發計劃,老年患者圍手術期中樞神經系統常見并發癥預警及綜合防治技術研究。
    4)2016-2019,國家自然科學基金課題,疼痛炎性因子對NCX調節神經病理性疼痛的機制研究。
    5)2016.01-2018.12,臨床科學家,中心高層次人才特殊支持項目。
    6)2013-2016,國家自然科學基金課題,NCX在神經病理性疼痛發病的作用和機制的研究。
    7)2013-2015,教育部博士點基金,鈉鈣交換蛋白在神經病理性疼痛機制的研究。 
    8)2013-2014 ,廣東省科技計劃項目,N-甲基-D-天冬氨酸受體抑制劑對肝細胞癌抑制增殖的作用及機制研究。
    9)2010-2012,國家自然科學基金課題,鞘內KB-R7943和SEA0400治療神經病理性疼痛的研究。
    10)2006-2008,國家自然科學基金課題,鞘內哇巴因和阿米洛利治療神經病理性疼痛的研究。
    11)2010-2012,廣東省科技計劃項目,鞘內KB-R7943和SEA0400治療神經病理性疼痛的研究。
    12)2002 ,“985”專項基金 神經病理性疼痛基礎和臨床綜合治療的研究。
    13)2000-2002,國家教育部回國人員啟動基金 脊髓內鈣、鉀通道在神經病理性疼痛中作用機理研究。

    三、指導的科研項目
    1)2011,廣東省科技計劃項目,鈉鈣交換蛋白在神經病理性疼痛中的表達。
    2)2010,廣東省科技計劃項目,肺復張/再灌注引起多器官氧化應激損傷的機制研究。
    3)2008,廣東省衛生廳基金,吸入麻醉對大鼠海馬乙酰膽堿釋放晝夜節律的影響。  
    4)2008,廣東省衛生廳基金,鈉、鉀泵抑制劑在脊髓內疼痛信號傳遞中作用的研究。
    5)2008,廣東省科技計劃項目,Na+-K+-ATP酶抑制劑哇巴因在脊髓內疼痛信號傳遞中作用的研究。
    6)2008,廣東省科技計劃項目,單肺通氣致雙側肺非均一性損傷的機制及姜黃素干預作用的研究。

    四、發表論著
    1)Amide-type local anesthetics may suppress tumor cell proliferation and sensitize Human Hepatocellular Carcinoma Cells to Cisplatin via upregulation of RASSF1A expression and demethylation. Journal of Cancer.2020, 7312-7319.(*)
    2)Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. Cancer communications. 2020;1–17.(*)
    3)Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma. Front. Oncol. 10:1360.doi: 10.3389/fonc.2020.013602020 August. (*)
    4)JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway. Eur J Pharmacol. 2020 Jun 27:173306. doi: 10.1016/j.ejphar.2020.173306. Online ahead of print. (*)
    5)Nuclear Factor-kappaB Gates Nav1.7 Channels in DRG Neurons via Protein-Protein Interaction. iScience. 2019 Aug 10;19:623-633. doi: 10.1016/j.isci.2019.08.017. [Epub ahead of print].
    6)Antinociceptive effectiveness of the inhibition of NCX reverse-mode action in rodent neuropathic pain model. Mol Pain. 2019 Jan-Dec;15:1744806919864511. doi: 10.1177/1744806919864511. (*)
    7)Sevoflurane promotes migration, invasion, and colony-forming ability of human glioblastoma cells possibly via increasing the expression of cell surface protein 44. Acta Pharmacol Sin. 2019 Apr 9. doi: 10.1038/s41401-019-0221-0. [Epub ahead of print].
    8)Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Nav1.8 β1 Subunit of Sensory Neurons. Front Pharmacol. 2019 Jan 7;9:1510. doi: 10.3389/fphar.2018.01510. eCollection 2018.
    9)Dexmedetomidine Protects Against Chemical Hypoxia-Induced Neurotoxicity in Differentiated PC12 Cells Via Inhibition of NADPH Oxidase 2-Mediated Oxidative Stress. Neurotox Res. Neurotox Res. 2019 Jan;35(1):139-149. doi: 10.1007/s12640-018-9938-7. Epub 2018 Aug 15. (*)
    10)The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019 Jun;122(6):e157-e167. doi: 10.1016/j.bja.2018.09.030. Epub 2018 Dec 12. (*)
    11)Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. Mol Pain. 2018 Jan-Dec;14:1744806918778491. doi: 10.1177/1744806918778491.
    12)Amantadine attenuates sepsis-induced cognitive dysfunction possibly not through inhibiting toll-like receptor 2. J Mol Med (Berl). 2018 May;96(5):391-402.
    13)Calpain-2 Regulates TNF-α Expression Associated with Neuropathic Pain Following Motor Nerve Injury. Neuroscience. 2018 Feb 23;376:142-151. 
    14)Early CALP2 expression and microglial activation are potential inducers of spinal IL-6 upregulation and bilateral pain following motor nerve injury. J Neurochem. 2018 Feb 9. doi: 10.1111/jnc.14317. [Epub ahead of print].
    15)AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4. Brain Behav Immun. 2018 Feb;68:158-168. 
    16)Synergistic Interaction Between Dexmedetomidine and Ulinastatin Against Vincristine-Induced Neuropathic Pain in Rats. J Pain. 2017 Nov;18(11):1354-1364.
    17)Down-regulation ofthe tumour suppressor κ-opioid receptor predicts  poor prognosis in hepatocellular carcinoma patients. BMC Cancer. 2017 Aug 18;17(1):553. (*)
    18)The Prognostic Value of Peripheral Benzodiazepine Receptor in Patients with Esophageal Squamous Cell Carcinoma. Journal of Cancer 2017, Vol. 8 2017; 8(16): 3343-3355. (*)
    19)Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. Anesthesiology. 2017 May;126(5):868-881. (*)
    20)Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies. BMC Cancer. 2016 Sep 22;16(1):747. (*)
    21)Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy. Cancer Biomark. 2016 Jun 7;17(1):89-96. (*)
    22)Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway. Molecular Pain. Volume 12: 1–9. (*)
    23)Presynaptic N-Methyl-d-aspartate (NMDA) Receptor Activity Is Increased Through Protein Kinase C in Paclitaxel-induced Neuropathic Pain. J Biol Chem. 2016 Sep 9;291(37):19364-73.
    24)Fentanyl enhances hepatotoxicity of paclitaxel via inhibition of CYP3A4 and ABCB1 transport activity in mice. PLoS One. 2015 Dec 3;10(12):e0143701. (*)
    25)Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. Pain Res Manag. 2015 Nov-Dec;20(6):321-6. (*)
    26)Antinociceptive effect of intrathecal amiloride on neuropathic pain in rats. Neurosci Lett. 2015 Jul 28;604:24-29. (*)
    27)Sevoflurane protects against intestinal ischemia-reperfusion injury partly by phosphatidylinositol 3 kinases/Akt pathway in rats. Surgery. 2015 May;157(5):924-33.
    28)Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014 Nov 18;14:844.(*)
    29)Anti-inflammatory and antinociceptive activities of bufalin in rodents. Mediators Inflamm. 2014;2014:171839.(*)
    30)Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesth Analg. 2014 Jun;118(6):1309-16 (*)
    31)HSV-mediated p55TNFSR reduces neuropathic pain induced by HIV gp120 in rats through CXCR4 activity. Gene Ther. 2014 Mar;21(3):328-36.
    32)Mechanical allodynia induced by nucleoside reverse transcriptase inhibitor is suppressed by p55TNFSR mediated by herpes simplex virus vector through the SDF1α/CXCR4 system in rats. Anesth Analg. 2014 Mar;118(3):671-80.
    33)Real-time Two-dimensional Ultrasound Guidance for Central Venous Cannulation: A Meta-analysis. Anesthesiology. 2013 Feb;118(2):361-75. (*)
    34)The antinociceptive activity of intrathecally administered amiloride and its interactions with morphine and clonidine in rats. J Pain. 2012 Jan;13(1):41-8. (*) 
    35)The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol. 2012 Oct;19(11):3556-65. (*)
    36)The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma. Anesth Analg. 2012  Feb;114(2):290-6.
    37)The antinociceptive effect of intrathecal escin in the rat formalin test. Eur J Pharmacol. 2012 Jan 15;674(2-3):234-8. (*)
    38)Risk factors for anastomotic leakage following anterior resection for colorectal cancer: the effect of epiduralanalgesia on occurrence. Int J Colorectal Dis. 2013 Apr;28(4):485-92. (*)
    39)An emerging new paradigm in opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray. Scientific World Journal. 2012:940613.  
    40)Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011 Jun;106(6):814-22. (*)
    41)Mechanisms of antinociceptive effects of ouabain in combination with neostigmine in the rat. Neural regeneration research 2008.3(7): 710-3. (*)
    42)Antinociceptive Synergistic Interaction between Clonidine and Ouabain on Thermal Nociceptive Tests in the Rat. J Pain 2007.8(12): 983-8. (*)
    43)Effects of succinylcholine on spinal antinociception with lidocaine in rats. Acute Pain 2005; 7(1):37-42. (*)
    44)Spinal antinociceptive action of Na+–K+ pump inhibitor ouabain and it interaction with morphine and lidocaine in rats. Anesthesiology 1999; 90: 500-8. (*)

    五、社會任職:
    1.廣東省醫學會疼痛學會分會第六屆主任委員
    2.廣東省抗癌協會腫瘤麻醉與鎮痛專業委員會榮譽主委
    3.中國心胸血管麻醉學會胸科麻醉分會副主任委員
    4.廣東醫學會麻醉分會常委
    5.廣東省醫師學會麻醉分會常委
    6.中華醫學會疼痛學分會第七、八屆委員會委員
    7.中山大學學報編委
    8.BMC Anesthesiology Associate Editor

    六、編著:
    1.癌癥疼痛的臨床治療 人民衛生出版社 副主編
    2.麻醉學考點 科學技術文獻出版社 副主編
    3.圍麻醉期風險與處理 人民衛生出版社 編委
    4.臨床麻醉意外與并發癥的預防和處理 人民衛生出版社 編委
    5.現代術后鎮痛學 廣東科技出版社 編委
    6.胸科腫瘤麻醉學 鄭州大學出版社 編委
    7.神經性疼痛診療學 鄭州大學出版社 編委
    8.2013麻醉學新進展 人民衛生出版社 編委
    9.圍術期臨床監測手冊 人民衛生出版社 編委


    更新日期:2021年2月24日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×
一女N男猛挺进肉多片段,农村妇女打野战视频在线观看,欧美肥老太牲交大战,日本熟妇中文无码